Klebsiella pneumoniae is currently considered as an immediate threat to human health due to its various multidrug efflux pumps. Microbially synthesized silver nanoparticles (AgNPs) are an attractive and eco-friendly approach to prevent antibiotic resistance in bacteria. In the present study, we compared the inhibitory effect of both commercial and green AgNPs by Bifidobacterium bifidum on OxqAB efflux pump genes in ciprofloxacin-resistant strains of K. pneumoniae.
Materials and Methods:
AgNPs were characterized by ultraviolet-visible spectrophotometer, Fourier transform infrared spectroscopy, X-ray diffraction, zeta potential, transmission electron microscopy, and scanning electron microscopy. Antibiogram was used to identify resistant isolates and the effect of the biosynthesized AgNPs against OxqAB efflux pump strains was assessed by the minimum inhibitory concentration (MIC) method. The expression levels of oxqAB genes were evaluated using real-time polymerase chain reaction (PCR) followed by exposure to subMICs of the AgNPs.
Results:
PCR results showed that 25 strains had OxqAB efflux pump and the MIC method indicated that AgNPs had an inhibitory effect on all resistant strains with OxqAB efflux pump. The efficacy of the synthetic nanoparticles was assessed by comparing the antiefflux pump activity with commercial AgNPs. In ciprofloxacin-resistant isolates, the oxqAB genes expression levels reduced in the subMIC of both AgNPs, whereas biosynthesized AgNPs had greater bactericidal effects compared with the commercial AgNPs.
Conclusions:
Efflux pumps could be an attractive target for our biosynthesized AgNPs. The oxqAB genes expression levels reduced in subMIC of both AgNPs, whereas biosynthesized AgNPs had greater bactericidal effects than the commercial AgNPs.
Get full access to this article
View all access options for this article.
References
1.
ManosalvaN., TortellaG., DiezM.C, SchalchliH., SeabraA.B, DuránN., and RubilarO.. 2019. Green synthesis of silver nanoparticles: effect of synthesis reaction parameters on antimicrobial activity. World J. Microbiol. Biotechnol. 35:88.
2.
MandalD., BolanderM.E, MukhopadhyayD., SarkarG., and MukherjeeP.. 2006. The use of microorganisms for the formation of metal nanoparticles and their application. Appl. Microbiol. Biotechnol. 69:485–492.
3.
WeiX., LuoM., LiW., YangL., LiangX., XuL., KongP., and LiuH.. 2012. Synthesis of silver nanoparticles by solar irradiation of cell-free Bacillus amyloliquefaciens extracts and AgNO3. Bioresour. Technol. 103:273–278.
4.
NarayananK.B., and SakthivelN.. 2010. Biological synthesis of metal nanoparticles by microbes. Adv. Colloid Interface Sci. 156:1–13.
5.
VimbelaG.V., NgoS.M, FrazeC., YangL., and StoutD.A.. 2017. Antibacterial properties and toxicity from metallic nanomaterials. Int. J. Nanomedicine. 12:3941.
6.
Clinical and Laboratory Standards Institute. 2009. Performance Standards for Antimicrobial Susceptibility Testing of Anaerobic Bacteria: Informational Supplement. Clinical and Laboratory Standards Institute (CLSI), Wayne, PA.
7.
GarmashevaI., KovalenkoN., VoychukS., OstapchukA., Livins'kaO., and OleschenkoL.. 2016. Lactobacillus species mediated synthesis of silver nanoparticles and their antibacterial activity against opportunistic pathogens in vitro. Bioimpacts, 6:219.
8.
ManitchotpisitP., BischoffK.M, PriceN.P, and LeathersT.D.. 2013. Bacillus spp. produce antibacterial activities against lactic acid bacteria that contaminate fuel ethanol plants. Curr. Microbiol. 66:443–449.
9.
Van BoeckelT.P., GandraS., AshokA., CaudronQ., GrenfellB.T, LevinS.A, and LaxminarayanR.. 2014. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect. Dis. 14:742–750.
10.
TammaP.D., and Rodriguez-BaňoJ.. 2017. The use of noncarbapenem β-lactams for the treatment of extended-spectrum β-lactamase infections. Clin. Infect. Dis. 64:972–980.
11.
ForoohimanjiliF., MirzaieA., HamdiS.M.M, NoorbazarganH., Hedayati ChM., DolatabadiA., RezaieH., and BishakF.M.. 2020. Antibacterial, antibiofilm, and antiquorum sensing activities of phytosynthesized silver nanoparticles fabricated from Mespilus germanica extract against multidrug resistance of Klebsiella pneumoniae clinical strains. J. Basic Microbiol. 60:216–230.
12.
van DuinD., and PatersonD.L.. 2016. Multidrug-resistant bacteria in the community: trends and lessons learned. Infect. Dis. Clin. 30:377–390.
13.
NikaidoH., and PagèsJ.-M.. 2012. Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria. FEMS Microbiol. Rev. 36:340–363.
14.
PerezF., RudinS.D, MarshallS.H, CoakleyP., ChenL., KreiswirthB.N, RatherP.N, HujerA.M, ToltzisP., and van DuinD.. 2013. OqxAB, a quinolone and olaquindox efflux pump, is widely distributed among multidrug-resistant Klebsiella pneumoniae isolates of human origin. Antimicrob. Agents Chemother. 57:4602–4603.
15.
LiJ., ZhangH., NingJ., SajidA., ChengG., YuanZ., and HaoH.. 2019. The nature and epidemiology of OqxAB, a multidrug efflux pump. Antimicrob. Resist. Infect. Control. 8:44.
16.
Bialek-DavenetS., LavigneJ.-P, GuyotK., MayerN., TournebizeR., BrisseS., Leflon-GuiboutV., and Nicolas-ChanoineM.-H.. 2014. Differential contribution of AcrAB and OqxAB efflux pumps to multidrug resistance and virulence in Klebsiella pneumoniae. J. Antimicrob. Chemother. 70:81–88.
17.
MoulaviP., NoorbazarganH., DolatabadiA., ForoohimanjiliF., TavakoliZ., MirzazadehS., HashemiM., and AshrafiF.. 2019. Antibiofilm effect of green engineered silver nanoparticles fabricated from Artemisia scoporia extract on the expression of icaA and icaR genes against multidrug-resistant Staphylococcus aureus. J. Basic Microbiol. 59:701–712.
18.
IniyanA.M., KannanR.R, F.-JosephJ.R.S, MaryT.R.J, RajasekarM., SumyP.C, RabelA.M, RamachandranD., and VincentS.G.P. 2017. In vivo safety evaluation of antibacterial silver chloride nanoparticles from Streptomyces exfoliatus ICN25 in zebrafish embryos. Microb. Pathog. 112:76–82.
19.
ShahM., FawcettD., SharmaS., TripathyS., and PoinernG.. 2015. Green synthesis of metallic nanoparticles via biological entities. Materials, 8:7278–7308.
20.
AlaviM., and KarimiN.. 2019. Biosynthesis of Ag and Cu NPs by secondary metabolites of usnic acid and thymol with biological macromolecules aggregation and antibacterial activities against multi drug resistant (MDR) bacteria. Int. J. Biol. Macromol. 128:893–901.
21.
KalimuthuK., BabuR.S, VenkataramanD., BilalM., and GurunathanS.. 2008. Biosynthesis of silver nanocrystals by Bacillus licheniformis. Colloids Surf. B Biointerfaces, 65:150–153.
22.
LeeS.H., and JunB.-H.. 2019. Silver nanoparticles: synthesis and application for nanomedicine. Int. J. Mol. Sci. 20:865.
23.
BhatiaD., MittalA., and MalikD.K.. 2016. Antimicrobial activity of PVP coated silver nanoparticles synthesized by Lysinibacillus varians. 3 Biotech 6:196.
24.
SaravananC., RajeshR., KaviarasanT., MuthukumarK., KavitakeD., and ShettyP.H.. 2017. Synthesis of silver nanoparticles using bacterial exopolysaccharide and its application for degradation of azo-dyes. Biotechnol. Rep. 15:33–40.
25.
KushwahaA., SinghV.K, BhartariyaJ., SinghP., and YasmeenK.. 2015. Isolation and identification of E. coli bacteria for the synthesis of silver nanoparticles: characterization of the particles and study of antibacterial activity. Eur. J. Exp. Biol. 5:65–70.
26.
RanganathE., RathodV., and BanuA.. 2012. Screening of Lactobacillus spp, for mediating the biosynthesis of silver nanoparticles from silver nitrate. IOSR PHR. 2:237–241.
27.
KumarA., GahlawatS.K, and KumarN.. 2016. Biosynthesis of silver nanoparticles using Bifidobacterium bifidum NCDC 229 and evaluation of synergistic effect with penicillin against pathogenic bacteria. Int. J. Sci. Nat. 7:614–621.
28.
ShankarC., VeeraraghavanB., NabarroL.E.B, RaviR., RagupathiN.K.D, and RupaliP.. 2018. Whole genome analysis of hypervirulent Klebsiella pneumoniae isolates from community and hospital acquired bloodstream infection. BMC Microbiol. 18:6.
29.
WongM.H.Y., ChanE.W.C, and ChenS.. 2015. Evolution and dissemination of OqxAB-like efflux pumps, an emerging quinolone resistance determinant among members of Enterobacteriaceae. Antimicrob. Agents Chemother. 59:3290–3297.
KimM., LeeJ.H, and NamJ.M.. 2019. Plasmonic photothermal nanoparticles for biomedical applications. Adv. Sci. 6:1900471.
32.
PezziL., PaneA., AnnesiF., LossoM.A, GuglielmelliA., UmetonC., and De SioL.. 2019. Antimicrobial effects of chemically functionalized and/or photo-heated nanoparticles. Materials. 12:1078.
33.
FardN.N., NoorbazarganH., MirzaieA., Hedayati ChM., MoghimiyanZ., and RahimiA.. 2018. Biogenic synthesis of AgNPs using Artemisia oliveriana extract and their biological activities for an effective treatment of lung cancer. Artif. Cells Nanomed. Biotechnol. 46:S1047–S1058.
34.
BehdadR., PargolM., MirzaieA., KariziS.Z, NoorbazarganH., and AkbarzadehI.. 2020. Efflux pump inhibitory activity of biologically synthesized silver nanoparticles against multidrug-resistant acinetobacter baumannii clinical isolates. J. Basic Microbiol. 60:494–507.
35.
Yun'an QingL.C., LiR., LiuG., ZhangY., TangX., WangJ., LiuH., and QinY.. 2018. Potential antibacterial mechanism of silver nanoparticles and the optimization of orthopedic implants by advanced modification technologies. Int. J. Nanomedicine, 13:3311.
36.
LiW.-R., XieX.-B, ShiQ.-S, ZengH.-Y, You-ShengO.-Y, and ChenY.-B.. 2010. Antibacterial activity and mechanism of silver nanoparticles on Escherichia coli. Appl. Microbiol. Biotechnol. 85:1115–1122.
37.
Soto, S.M. 2013. Role of efflux pumps in the antibiotic resistance of bacteria embedded in a biofilm. Virulence, 4:223–229.
38.
LeeA., MaoW., WarrenM.S, MistryA., HoshinoK., OkumuraR., IshidaH., and LomovskayaO.. 2000. Interplay between efflux pumps may provide either additive or multiplicative effects on drug resistance. J. Bacteriol. 182:3142–3150.
39.
Da SilvaC., PetersG.J, OssendorpF., and CruzL.J.. 2017. The potential of multi-compound nanoparticles to bypass drug resistance in cancer. Cancer Chemother. Pharmacol. 80:881–894.
40.
BarrosC., FulazS., StanisicD., and TasicL.. 2018. Biogenic nanosilver against multidrug-resistant bacteria (MDRB). Antibiotics, 7:69.
41.
SzaboO., KocsisB., SzaboN., KristofK., and SzaboD.. 2018. Contribution of OqxAB efflux pump in selection of fluoroquinolone-resistant Klebsiella pneumoniae. Can. J. Infect. Dis. Med. Microbiol. 2018:47271638.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
